GlassScriptPhysician profile
Parissa Moradi
NPI 1043448731
$2,007.59
in general payments reported to CMS, 2019-2025
28 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.61 · 2022: $85.22 · 2023: $161 · 2024: $727 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.82 | 2024-2025 | |
| Organon LLC | $179.01 | 2021-2024 | Nexplanon |
| Viiv Healthcare Company | $163.59 | 2024-2025 | Apretude |
| Gilead Sciences, INC. | $119.29 | 2025 | |
| Braeburn INC. | $109.35 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.99 | 2025 | Caplyta |
| Amgen INC. | $82.76 | 2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $69.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $67.76 | 2024-2025 | Zepbound, Mounjaro |
| Sage Therapeutics, LLC | $55.62 | 2025 | Zurzuvae |
| Paratek Pharmaceuticals, INC. | $53.15 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $52.58 | 2022-2024 | Gardasil 9, Gardasil, M-M-R II |
| Novo Nordisk INC | $51.96 | 2024-2025 | Wegovy |
| Sanofi Pasteur INC. | $50.34 | 2024 | |
| Sumitomo Pharma America, INC. | $49.40 | 2023 | Myfembree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $40.91 | 2024 | Sublocade |
| Madrigal Pharmaceuticals | $36.82 | 2024 | Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $31.36 | 2024 | |
| Averitas Pharma INC. | $31.31 | 2025 | Qutenza |
| Dexcom, INC. | $28.14 | 2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $25.48 | 2025 | Qelbree |
| Hologic Sales and Service, LLC | $24.56 | 2024 | Aptima, Thinprep 2000 Processor |
| Alkermes, INC. | $24.42 | 2024 | Vivitrol |
| Immunogen, INC. | $23.69 | 2023 | Elahere |
| Astellas Pharma US INC | $23.62 | 2024 | Veozah |
| Abbott Laboratories | $21.46 | 2024 | Piccolo Xpress |
| Reprise Biomedical, INC. | $19.09 | 2024 | Miro3d |
| Cipher Pharmaceuticals US LLC | $18.52 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parissa Moradi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.